Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru

BMC Public Health

Table 2 Predicted health impact of PCVs in Peru during the first 10 years of life (undiscounted data)

	No vaccination		PCV-7			PCV-13			PHiD-CV
	Cases^a	Rate^b	Cases^a	Rate^b	Averted (%)	Cases^a	Rate^b	Averted (%)	Cases^a	Rate^b	Averted (%)
Cases
Pneumococcal meningitis	177	35.4	142	28.4	19.8	129	25.8	27.1	131	26.2	26.0
NTHi meningitis	16	3.2	16	3.2	0.0	16	3.2	0.0	14	2.8	12.5
Pneumococcal bacteremia	495	98.9	350	69.9	29.3	295	58.9	40.4	303	60.5	38.8
NTHi bacteremia	30	6.0	30	6.0	0.0	30	6.0	0.0	25	5.0	16.7
Hospitalized pneumonia	37,110	7,412	32,585	6,508	12.2	31,930	6,377	14.0	31,930	6,377	14.0
Ambulatory pneumonia	39,352	7,859	38,404	7,670	2.4	38,268	7,643	2.8	38,267	7,643	2.8
AOM	306,989	61,312	297,535	59,424	3.1	286,598	57,239	6.6	270,573	54,039	11.9
Myringotomies	7,193	1,437	6,315	1,261	12.2	5,325	1,064	26.0	3,838	767	46.6
Deaths
Pneumococcal meningitis	9.7	1.9	7.2	1.4	26.2	6.2	1.2	36.0	6.4	1.3	34.5
NTHi meningitis	1.6	0.3	1.6	0.3	0.0	1.6	0.3	0.0	1.4	0.3	10.9
Pneumococcal bacteremia	76.2	15.2	53.4	10.7	30.0	44.7	8.9	41.3	46.1	9.2	39.6
NTHi bacteremia	3.0	0.6	3.0	0.6	0.0	3.0	0.6	0.0	2.5	0.5	17.2
Pneumonias	1,212.0	242.1	1,078.4	215.4	11.0	1,059.0	211.5	12.6	1,059.0	211.5	12.6
Total	1,302.5	260.1	1,143.5	228.4	12.2	1,114.6	222.6	14.4	1,115.4	222.8	14.4

^aCases and deaths during the first 10 years of life.
^bRates expressed per 100,000 individuals.
AOM, acute otitis media; NTHi, non-typeable Haemophilus influenzae; PCV-7, 7-valent pneumococcal conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine.

ISSN: 1471-2458